Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers.

Frontiers in immunology - 1 Jan 2022

Ji Wenxiang, Niu Xiaomin, Yu Yongfeng, Li Ziming, Gu LinPing, Lu Shun

Abstract excerpt

Background: The emergence of immune checkpoint inhibitors (ICIs) is one of the most promising breakthroughs for the treatment of multiple cancer types, but responses vary. Growing evidence points to a link between developmental signaling pathway-related genes and antitumor immunity, but the association between the genomic alterations in these genes and the response to ICIs still needs to be elucidated. Methods:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Mutation

Share to Smoothened Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 36405701
DOI: 10.3389/fimmu.2022.955800
PMCID: PMC9669061

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers.PMID 36405701Read ↗

SMO mutation affects tumor immuno-microenvironment and predicts the effect of immune checkpoint inhibitor: from NSCLC to multiple-cancersSemantic proximity Read ↗

Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy.Semantic proximity Read ↗

Association of EYS mutations with immune checkpoint inhibitor outcome and response in melanoma and non-small cell lung cancerSemantic proximity Read ↗

Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, other than Abscopal Effect: A Systematic ReviewSemantic proximity Read ↗

Genomic and Transcriptomic Landscape of an Oral Squamous Cell Carcinoma Mouse Model for ImmunotherapySemantic proximity Read ↗

mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.Semantic proximity Read ↗

BRAF mutation predicts survival after immunotherapy across multiple cancer types.Semantic proximity Read ↗

ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.Semantic proximity Read ↗

Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma.Semantic proximity Read ↗

De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.